VP Pence to Talk Trade, Security During Trip to Australia
Global march for science raises concern over Trump policies
You can now read, compose and send WhatsApp messages via Siri
New Deal Aims To Bridge Republican Health Care Divide
French police seeks possible second suspect in Paris shooting
Agios Pharmaceuticals Inc (AGIO) Director Sells $112468.64 in Stock
21 April 2017, 02:17 | Megan Pierce
Essentially, a price target is an individual analyst's expectation on the future price of a security, usually a stock.
On 4/3/2017 Scott Biller, Insider, sold 2,146 with an average share price of $58.03 per share and the total transaction amounting to $124,532.38.
Agios Pharmaceuticals, Inc.is a biopharmaceutical company, which engages in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. They now have a Dollars 45 price target on the stock.
On Thursday, March 23rd, Lewis Clayton Jr. BNP Paribas Arbitrage SA now owns 14,388 shares of the biopharmaceutical company's stock valued at $760,000 after buying an additional 2,440 shares during the period. Highest potential price target is expected at $90.00 however minimum price target advised by analysts is $48.00.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 3,000 shares of the business's stock in a transaction dated Monday, April 3rd. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price.
The stock's 50 day moving average is 53.56 and its 200 day moving average is 50.55.
Analysts gives Agios Pharmaceuticals Inc (NASDAQ:AGIO) a mean recommendation of 1.90. Beta value of the stock stands at 2.00. Agios Pharmaceuticals's revenue for the quarter was up 264.5% compared to the same quarter previous year. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.51) by $0.17. The firm earned $22.65 million during the quarter, compared to the consensus estimate of $10.89 million. Rhumbline Advisers boosted its stake in Agios Pharmaceuticals by 3.4% in the third quarter. The company's quarterly revenue was up 264.5% compared to the same quarter a year ago. Annual EPS Growth of past 5 years is 10.60%. (AGIO) has a trading volume of 4.11 Million shares, with an average trading volume of 453120 shares - with shares dropping to a 52 week low of $35.84, and the company's shares hitting a 52 week high of $ 67.74. The legal version of this story can be read at https://www.thecerbatgem.com/2017/04/20/agios-pharmaceuticals-inc-agio-ceo-sells-175860-00-in-stock-updated.html. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & worldwide copyright and trademark legislation. Zacks Investment Research cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday. The firm has "Neutral" rating given on Friday, August 19 by BTIG Research. Beech Hill Advisors Inc. purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $217,000.
At the time of writing, Agios Pharmaceuticals, Inc. Janney Montgomery Scott upgraded shares of Agios Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $57.00 price objective for the company in a research report on Thursday, February 16th. The Stock opened today's session at $27 and now the price is hovering at $26.87 by showing decrease of -0.07 percent. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. They now have a Dollars 46 price target on the stock.
Large investors have recently modified their holdings of the company.
05/08/2015 - MLV & Co began new coverage on Agios Pharmaceuticals, Inc. giving the company a "buy" rating. The volatility in the previous week has experienced by 4.84% and observed of 4.60% in the previous month.97.60% ownership is held by institutional investors while insiders hold ownership of 0.50%. Capital International Ltd. CA raised its stake in shares of Agios Pharmaceuticals by 31.0% in the fourth quarter.
06/13/2016 - Agios Pharmaceuticals, Inc. was upgraded to "overweight" by analysts at JP Morgan.
2 officers shot responding to robbery in Seattle
Police are searching for a possible third suspect: A black man with a dark complexion, 5 feet 11 inches tall and 250 pounds. "Wow. A female suspect struck one of the officers with a bottle and a third suspect opened fire, wounding the officers, police said.
South Korea-US trade deal will be reviewed, reformed - VP Pence
In Wisconsin on Tuesday, Trump said that how much North Korea's leader desires peace will be a deciding factor in easing tensions. Pence said after the meeting that Trump believes it is in America's interest to negotiate economic deals on a bilateral basis.
Drive-thru pot stores are now a reality
When the "for sale" sign went up on the Valley Car Wash in Parachute , Colo., Mark Smith didn't waste a second. So he bought the auto wash and set to work transforming the vehicle bay into a new place to sell his wares.
What Do Analysts Say About GNC Holdings Inc. (GNC)
In addition to Vetr Inc. reporting its stock price target , a total of 13 brokerages have issued a ratings update on the company. In terms of Buy/Sell recommendations, analysts have a consensus rating of 3.18 on the shares of GNC Holdings Inc (NYSE: GNC ).
Manchester City climb to third with Southampton victory
He's a real defender, hopefully he can be fit until the end of the season because he's an important player for us". Everton are lining up a summer move for Manchester City captain Vincent Kompany, according to the Daily Mirror .